Impact of bone marrow morphology on multivariate risk classification in chronic myelogenous leukemia

Acta Haematol. 2003;109(1):53-6. doi: 10.1159/000067278.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Bone Marrow / pathology*
  • Erythroid Precursor Cells / drug effects
  • Female
  • Humans
  • Hydroxyurea / administration & dosage
  • Hydroxyurea / pharmacology
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / pharmacology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Primary Myelofibrosis / drug therapy
  • Prognosis
  • Recombinant Proteins
  • Risk Assessment
  • Survival Analysis

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Hydroxyurea